Benefits of G-CSF After High-Dose Chemotherapy for Lymphoma
Author Information
Author(s): SM Lee, JA Radford, L Dobson, T Huq, WDJ Ryder, R Pettengell, GR Morgenstern, JH Scarffe, D Crowther
Primary Institution: Christie Hospital NHS Trust
Hypothesis
Does the use of G-CSF after high-dose chemotherapy improve recovery and reduce costs in patients with high-grade non-Hodgkin's lymphoma?
Conclusion
The use of G-CSF after high-dose chemotherapy leads to faster recovery and shorter hospital stays without increasing healthcare costs.
Supporting Evidence
- Patients receiving G-CSF had a mean recovery time of 9.7 days compared to 13.2 days for those without G-CSF.
- The median duration of hospital stay was shorter for the G-CSF group at 12 days versus 15 days for the control group.
- Despite the cost of G-CSF, the overall healthcare expenditure was lower in the G-CSF group.
Takeaway
Giving G-CSF helps patients recover faster after chemotherapy and they spend less time in the hospital, which is good for both them and the hospital's budget.
Methodology
A prospective randomized trial comparing PBPC alone versus PBPC with G-CSF in patients with high-grade non-Hodgkin's lymphoma.
Limitations
The study had a small sample size and was limited to patients under 60 years old.
Participant Demographics
Patients were aged less than 60 years with poor-prognosis high-grade non-Hodgkin's lymphoma.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI of 2.2-4.8 days for granulocyte recovery time
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website